Oral Ozanimod for Crohn's Disease

"Ozanimod has some efficacy data from previous trials, and multiple rounds of safety testing have been completed, so it received a score of 3."

"There have been 11 ongoing studies for Ozanimod in 52 countries and 287 cities since 2015. The first study, sponsored by Celgene, was completed in Phase 3 drug approval stage with 2350 participants."

"This clinical trial is presently enrolling patients at 77 sites. The locations are located in San Francisco, Bristol and Decatur as well as 77 other locations. It is important to select the site closest you so that you can minimize travel demands if you enroll."

"Ileocolitis patients, between the ages of 18-75, who meet the following medical criteria are encouraged to apply: Must not have ulcerative colitis, an inadequate response or loss of response to corticosteroids, immunomodulators, and/or biologic therapy."

"Ozanimod was first studied in the year 2015 at Local Institution - 554. Out of the 18302 completed trials, 11 are ongoing with many taking place in San Francisco, California."

"Yes, you are correct. The clinical trial was originally posted on 3/7/2018 and was last updated on 11/15/2022. The study is enrolling 600 patients across 77 sites."

"The age range for eligible patients in this study is between 18 and 75 years old."

"Ozanimod is a medication that can help patients suffering from sclerosis, multiple sclerosis, and carcinoma in situ."

"The trial is still ongoing and recruiting patients, according to the information provided on clinicaltrials.gov. The listing for the study was first posted on March 7th, 2018 with the most recent update being from November 15th, 2020."